By the closing bell, the S&P 500 had booked its biggest weekly gain since October 2023 and the Nasdaq since November 2022.

The average country ETF is down 4% since 4/2, so SPY has underperformed that since Trump's Rose Garden announcement. Asian ...

Consumer price inflation fell to 2.4% in March, surprising analysts who expected a rise, but future inflation concerns remain ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

Tevogen Bio faces hurdles with unclear COVID-19 therapy demand, ambitious projections, and risks ahead. Click here to read an ...

Apple Inc.'s market value declines amid tariff controversy. Discover why its valuation remains unattractive and growth ...

Dr. Maguire is an ardent, experienced value investor. Most of his career has been spent as a healthcare executive and business owner, caring for patients diagnosed with cancer in coastal North ...

The 200DMA Signal suggests S&P 500 Index losses amidst U.S.-China tensions. Click for my look at technical triggers for the ...

Recursion Pharmaceuticals' stock is soaring today on news the FDA is planning on phasing out some animal testing, replacing ...

Celestica reports 21% YoY revenue growth in CY 2024, driven by CCS expansion. Click here to find out why CLS stock is a Buy.

Recuresion Pharma (RXRX) stock and other AI-driven biotechs surge as FDA embraces computational models over animal testing ...

RTX Corporation is a strategic player in aerospace and defense, benefiting from economies of scale, cross-innovation, and ...